EUVIMEDEUVIMED entdecken
Crossref

T-VEC in the palliative treatment of Mucosal Melanoma

Kerstin Stähr, Lisa Zimmer, Elisabeth Livingstone, Christoph Pöttgen, Stefan Mattheis, Stephan Lang, Friederike Kaster

Laryngo-Rhino-Otologie · 01.05.2024 · 103 (S 02 S 02) · S319

DOI: 10.1055/s-0044-1785079 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Laryngo-Rhino-Otologie, erschienen am 01.05.2024. Verfasst von Kerstin Stähr und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Intralesional injection of oncolytic viral immunotherapies leads to apoptosis of tumour cells and induction of an immune response. Talimogene laherparepvec (T-VEC) is approved for the treatment of malignant melanoma in non-resectable and metastatic settings. Patients/Methods We present the case of a 61-year-old patient with malignant mucosal melanoma of the nasal cavity and sinuses. After multiple previous surgeries and radiotherapy, during immunotherapy with nivolumab local tumor progression was detected. The tumor was inoperable. In accordance with the interdisciplinary tumor board, multiple endoscopically controlled local injections with T-VEC were performed an immunotherapy with nivolumab and ipilimumab was started.

Results

The patient received a total of 8 intralesional injections of T-VEC. The findings showed complete regression. The regular endoscopic check-ups showed no evidence of local tumor growth over the course of 5 months. Post-interventionally, the patient suffered from flu-like symptoms with a slight fever for about 24 hours.

Discussion

T-VEC is successfully used with a manageable side effect profile in the palliative setting for local tumor control. In further studies, neoadjuvant therapy for locally advanced tumours could be tested. T-VEC can be discussed as an off-label treatment option for refractory mucosal melanomas or in neoadjuvant therapy Publication History Article published online: 19 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Stähr, K., Zimmer, L., Livingstone, E., Pöttgen, C., Mattheis, S., Lang, S., & Kaster, F. (2024). T-VEC in the palliative treatment of Mucosal Melanoma. Laryngo-Rhino-Otologie, 103(S 02 S 02), S319. https://doi.org/10.1055/s-0044-1785079

Vancouver

Stähr K, Zimmer L, Livingstone E, Pöttgen C, Mattheis S, Lang S, et al. T-VEC in the palliative treatment of Mucosal Melanoma. Laryngo-Rhino-Otologie. 2024;103(S 02 S 02):S319. doi:10.1055/s-0044-1785079

BibTeX
@article{Sthr2024,
  author = {Stähr, Kerstin and Zimmer, Lisa and Livingstone, Elisabeth and Pöttgen, Christoph and Mattheis, Stefan and Lang, Stephan and Kaster, Friederike},
  title = {T-VEC in the palliative treatment of Mucosal Melanoma},
  journal = {Laryngo-Rhino-Otologie},
  year = {2024},
  volume = {103},
  number = {S 02 S 02},
  pages = {S319},
  doi = {10.1055/s-0044-1785079}
}
Kostenlos starten →